Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Capital Expenditures (2024 - 2025)

Silence Therapeutics' Capital Expenditures history spans 2 years, with the latest figure at $3000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 95.31% year-over-year to $3000.0; the TTM value through Dec 2025 reached $55000.0, down 73.93%, while the annual FY2025 figure was $55000.0, 73.93% down from the prior year.
  • Capital Expenditures for Q3 2025 was $3000.0 at Silence Therapeutics, down from $48000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $85000.0 in Q2 2024 and bottomed at $3000.0 in Q3 2025.